Literature DB >> 15932171

A negative Helicobacter pylori serology test is more reliable for exclusion of premalignant gastric conditions than a negative test for current H. pylori infection: a report on histology and H. pylori detection in the general adult population.

Tom Storskrubb1, Pertti Aro, Jukka Ronkainen, Michael Vieth, Manfred Stolte, Karin Wreiber, Lars Engstrand, Henry Nyhlin, Elisabeth Bolling-Sternevald, Nicholas J Talley, Lars Agréus.   

Abstract

OBJECTIVE: Corpus-dominant gastritis, gastric mucosal atrophy and intestinal metaplasia (IM) associated with Helicobacter pylori infection are all known potential risk markers for the development of gastric cancer. As the accuracy for finding cases at risk in the general population is unknown, we aimed to determine the prevalence of current and/or past H. pylori infection and associated gastric mucosal findings by means of histological survey of a random adult population.
MATERIAL AND METHODS: A random Swedish sample (n = 3000, age 20-81 years) was surveyed using a validated gastrointestinal symptom questionnaire with 74% response rate. One-third of the responders were selected at random for esophago-gastro-duodenoscopy with biopsies and H. pylori serology.
RESULTS: Of those endoscoped (n = 1000, mean age 53.5, 51% women), 43.0% were H. pylori+ by serology (seropositive), 33.9% had signs of current infection on either histology or culture (gold standard+), and 9.3% were seropositive, but gold standard negative. Corpus atrophy was found in 10% and IM in 13% when gold standard positive, and in a significantly higher number (17% and 21%, respectively) of those with only a serological sign of past infection. Among those who were seronegative, values were 1% and 2%, respectively. Corpus-dominant gastritis was found in 4.1%, all seropositive.
CONCLUSION: One-third had an ongoing H. pylori infection, and a further 10% had signs of past infection. Corpus-dominant gastritis was found mostly among the former, while detection of those with corpus atrophy and IM also required a test for past infection. Seronegativity almost excludes precancerous conditions in a screening situation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15932171     DOI: 10.1080/00365520410010625

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  16 in total

1.  Towards a healthy stomach? Helicobacter pylori prevalence has dramatically decreased over 23 years in adults in a Swedish community.

Authors:  Lars Agréus; Per M Hellström; Nicholas J Talley; Bengt Wallner; Anna Forsberg; Michael Vieth; Lothar Veits; Karin Björkegren; Lars Engstrand; Anna Andreasson
Journal:  United European Gastroenterol J       Date:  2015-12-18       Impact factor: 4.623

2.  In vivo sequence variation in HopZ, a phase-variable outer membrane protein of Helicobacter pylori.

Authors:  Lynn Kennemann; Birgit Brenneke; Sönke Andres; Lars Engstrand; Thomas F Meyer; Toni Aebischer; Christine Josenhans; Sebastian Suerbaum
Journal:  Infect Immun       Date:  2012-10-01       Impact factor: 3.441

3.  The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: evolution during disease progression.

Authors:  Jung D Oh; Helene Kling-Bäckhed; Marios Giannakis; Jian Xu; Robert S Fulton; Lucinda A Fulton; Holland S Cordum; Chunyan Wang; Glendoria Elliott; Jennifer Edwards; Elaine R Mardis; Lars G Engstrand; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-20       Impact factor: 11.205

4.  Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study.

Authors:  Jukka Ronkainen; Nicholas J Talley; Pertti Aro; Tom Storskrubb; Sven-Erik Johansson; Tore Lind; Elisabeth Bolling-Sternevald; Michael Vieth; Manfred Stolte; Marjorie M Walker; Lars Agréus
Journal:  Gut       Date:  2006-11-29       Impact factor: 23.059

5.  Use of tobacco products and gastrointestinal morbidity: an endoscopic population-based study (the Kalixanda study).

Authors:  Pertti Aro; Jukka Ronkainen; Tom Storskrubb; Michael Vieth; Lars Engstrand; Sven-Erik Johansson; Elisabeth Bolling-Sternevald; Gunilla Bolinder; Kjell Alving; Nicholas J Talley; Lars Agréus
Journal:  Eur J Epidemiol       Date:  2010-07-29       Impact factor: 8.082

6.  Accuracy of Helicobacter pylori serology in two peptic ulcer populations and in healthy controls.

Authors:  Rolv-Ole Lindsetmo; Roar Johnsen; Tor Jac Eide; Tore Gutteberg; Hanne Haukland Husum; Arthur Revhaug
Journal:  World J Gastroenterol       Date:  2008-08-28       Impact factor: 5.742

7.  Functional analysis of the M.HpyAIV DNA methyltransferase of Helicobacter pylori.

Authors:  Anna Skoglund; Britta Björkholm; Christina Nilsson; Anders F Andersson; Cecilia Jernberg; Katja Schirwitz; Cristofer Enroth; Margareta Krabbe; Lars Engstrand
Journal:  J Bacteriol       Date:  2007-10-05       Impact factor: 3.490

8.  Association of autoimmune type atrophic corpus gastritis with Helicobacter pylori infection.

Authors:  Lea Irene Veijola; Aino Mirjam Oksanen; Pentti Ilmari Sipponen; Hilpi Iris Kaarina Rautelin
Journal:  World J Gastroenterol       Date:  2010-01-07       Impact factor: 5.742

9.  A changing gastric environment leads to adaptation of lipopolysaccharide variants in Helicobacter pylori populations during colonization.

Authors:  Anna Skoglund; Helene Kling Bäckhed; Christina Nilsson; Britta Björkholm; Staffan Normark; Lars Engstrand
Journal:  PLoS One       Date:  2009-06-11       Impact factor: 3.240

10.  Response of gastric epithelial progenitors to Helicobacter pylori Isolates obtained from Swedish patients with chronic atrophic gastritis.

Authors:  Marios Giannakis; Helene Kling Bäckhed; Swaine L Chen; Jeremiah J Faith; Meng Wu; Janaki L Guruge; Lars Engstrand; Jeffrey I Gordon
Journal:  J Biol Chem       Date:  2009-09-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.